Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with advanced immunological conditions. The company targets validated biology in respiratory and dermatology.
Products, services, technology
WIN378 is a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in Phase 2. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific, which has broad therapeutic application across immunological diseases.
Cooperation possibilities
We are interested in partnering in research, development, and commercialization with organizations that can advance our mission.
- http://www.windwardbio.com
- +41 61 551 75 75
- Send an email
- Kevin Harris
Some insights
We develop innovative therapies for severe immunological diseases including respiratory and dermatology, aiming to improve outcomes for patients with high unmet medical needs and provide them with better outcomes and quality of life.
We combine strong science with humility, speed, and integrity, always focused on patients. We advance medicines the right way, with trust, collaboration, and a team that truly cares.
Deep research and development expertise, strong collaboration, doer mindset, comfort with ambiguity and successful track record, both collectively individually. Looking ahead, we aim to add more late-stage development and commercialization capabilities as we grow.
We try to bring new medicines to people living with advanced stages of asthma, COPD, and other respiratory and skin diseases. We do this by working as a team to solve complex challenges together.
Academic innovators, clinical experts, biotech peers, investors, regulators, and partners who share a patient-first mindset and want to build long-term impact together.